Clinical Report: Imbalance of Regulatory T Cells in Vitiligo
Overview
This review highlights the dysregulation of regulatory T cells (Tregs) in vitiligo, revealing reduced Treg frequency and impaired function in both peripheral blood and lesional skin. The findings suggest that Treg abnormalities contribute to the persistence of autoimmune attacks on melanocytes.
Background
Vitiligo is an autoimmune skin disorder characterized by the destruction of melanocytes by CD8+ T cells, leading to depigmentation. Understanding the role of Tregs in maintaining immune tolerance is crucial, as their dysfunction is implicated in the pathogenesis of vitiligo. This review aims to integrate insights on Treg biology and their therapeutic potential in managing vitiligo.
Data Highlights
No numerical data available.
Key Findings
Vitiligo patients show reduced Treg frequency and impaired suppressive capacity in peripheral blood.
Lesional skin exhibits a marked decrease in tissue-resident and antigen-specific Treg subsets.
Systemic Treg deficits contribute to insufficient suppression of autoreactive CD8+ T cells.
Therapeutic strategies such as NB-UVB, JAK inhibitors, and low-dose IL-2 may help restore immune balance.
Emerging Treg subsets could serve as biomarkers for treatment response in vitiligo.
Clinical Implications
Clinicians should consider the role of Tregs in vitiligo management, as their dysfunction may exacerbate disease progression. Targeted therapies aimed at restoring Treg function could enhance treatment outcomes and improve patient quality of life.
Conclusion
The findings underscore the importance of Treg dysregulation in vitiligo and highlight potential therapeutic avenues to restore immune balance. Further research into Treg-targeted strategies may lead to improved management of this condition.
